93 related articles for article (PubMed ID: 21082504)
1. Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose.
Olivennes F
Semin Reprod Med; 2010 Nov; 28(6):463-7. PubMed ID: 21082504
[TBL] [Abstract][Full Text] [Related]
2. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.
Olivennes F; Howies CM; Borini A; Germond M; Trew G; Wikland M; Zegers-Hochschild F; Saunders H; Alam V
Reprod Biomed Online; 2011 Feb; 22 Suppl 1():S73-82. PubMed ID: 21575853
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation syndrome prevention strategies: oral contraceptive pills-dual gonadotropin-releasing hormone agonist suppression with step-down gonadotropin protocols.
Damario MA
Semin Reprod Med; 2010 Nov; 28(6):468-74. PubMed ID: 21082505
[TBL] [Abstract][Full Text] [Related]
4. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.
Olivennes F; Howles CM; Borini A; Germond M; Trew G; Wikland M; Zegers-Hochschild F; Saunders H; Alam V;
Reprod Biomed Online; 2009 Feb; 18(2):195-204. PubMed ID: 19192339
[TBL] [Abstract][Full Text] [Related]
5. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
Kashyap S; Parker K; Cedars MI; Rosenwaks Z
Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
[TBL] [Abstract][Full Text] [Related]
6. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
7. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.
Mathur R; Kailasam C; Jenkins J
Hum Fertil (Camb); 2007 Jun; 10(2):75-85. PubMed ID: 17564886
[TBL] [Abstract][Full Text] [Related]
8. Preventing ovarian hyperstimulation syndrome: guidance for the clinician.
Humaidan P; Quartarolo J; Papanikolaou EG
Fertil Steril; 2010 Jul; 94(2):389-400. PubMed ID: 20416867
[TBL] [Abstract][Full Text] [Related]
9. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome.
Várnagy A; Bódis J; Mánfai Z; Wilhelm F; Busznyák C; Koppán M
Fertil Steril; 2010 May; 93(7):2281-4. PubMed ID: 19261278
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa.
Olivennes F; Trew G; Borini A; Broekmans F; Arriagada P; Warne DW; Howles CM
Reprod Biomed Online; 2015 Mar; 30(3):248-57. PubMed ID: 25596910
[TBL] [Abstract][Full Text] [Related]
11. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.
Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ
BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
Griesinger G
Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the gonadotrophin dose regimen.
Out HJ; Thomas LE
Int Surg; 2006; 91(5 Suppl):S15-24. PubMed ID: 17436601
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
Kol S; Itskovitz-Eldor J
Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
[TBL] [Abstract][Full Text] [Related]
15. Identification of the high-risk patient for ovarian hyperstimulation syndrome.
Papanikolaou EG; Humaidan P; Polyzos NP; Tarlatzis B
Semin Reprod Med; 2010 Nov; 28(6):458-62. PubMed ID: 21082503
[TBL] [Abstract][Full Text] [Related]
16. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
[TBL] [Abstract][Full Text] [Related]
17. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
[TBL] [Abstract][Full Text] [Related]
18. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
[TBL] [Abstract][Full Text] [Related]
19. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
20. Ovarian hyperstimulation syndrome prevention strategies: Luteal support strategies to optimize pregnancy success in cycles with gonadotropin-releasing hormone agonist ovulatory trigger.
Engmann L; Benadiva C
Semin Reprod Med; 2010 Nov; 28(6):506-12. PubMed ID: 21082510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
